Lourdes Farre

Lourdes Farre

Auto-generated profile, based on publicly available information

Lourdes Farre

Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO)

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ADAngel Diaz-Lagares
Angel Diaz-Lagares
Ana B. CrujeirasAna B. Crujeiras
Ana B. Crujeiras
PLPaula Lopez-Serra
Paula Lopez-Serra
MSMarta Soler
Marta Soler
FSFernando Setien
Fernando Setien
MEManel Esteller
Manel Esteller
Significance: Long noncoding RNAs (lncRNAs) are starting to be recognized as critical molecules for cellular transformation, although only a few candidates have so far been characterized. Here we report that TP53TG1 is an lncRNA that is critical for the correct response of p53 to DNA damage. The cancer growth suppressor features of TP53TG1 are linked to its ability to block the tumorigenic activity of the RNA binding protein YBX1. The DNA methylation-associated silencing of TP53TG1 produces aggressive tumors that are resistant to cellular death when DNA-damaging agents and small targeted molecules are used. Our study provides an example of a tumor suppressor lncRNA undergoing an epigenetic lesion in cancer that is placed at the crossroads of DNA damage and oncogenic pathways.


1 January 2009 in Acta Oncologica
Verified
Journal Article
Closed access
ABAchiléa L. Bittencourt
Achiléa L. Bittencourt
HBHelenemarie S. Barbosa
Helenemarie S. Barbosa
MVMaria Das Graças Vieira
Maria Das Graças Vieira
LFLourdes Farré
Lourdes Farré
Adult T-cell leukemia/lymphoma (ATL) is a severe disease caused by HTLV-I. This paper describes the clinicopathological and immunohistochemical findings of 52 cases of ATL with skin involvement and investigates whether there is any relationship between median survival time (MST) and histological patterns, primary cutaneous involvement and CD8 positivity. All cases were HTLV-I+ and HIV- and were clinically classified. HTLV-I proviral integration was investigated in atypical cases. Immunohistochemistry was performed using CD3, CD4, CD5, CD7, CD8, CD20, CD25, CD30 and CD45RO markers. Ki-67 was used to evaluate the proliferative index. Twenty-seven cases were primary, while 25 were secondary. Monoclonal viral integration was demonstrated in all atypical cases. Patterns resembling mycosis fungoides (MF) were found in 19 cases and anaplastic large-cell lymphoma (ALCL) in two cases. Fifteen cases had an atypical immunophenotype and expressed CD8. Primary cutaneous ATL had a longer MST (48 months) than the secondary cutaneous ATL (7 months) and the difference was statistically significant, but no statistically significant difference was found between the MST of CD8-positive and negative cases. It is important to differentiate between primary and secondary cutaneous ATL and classify the cases histologically in order to better evaluate the prognosis. The two forms of primary cutaneous ATL, primary cutaneous smoldering and primary cutaneous tumoral (PCT), should also be identified. The smoldering type presented a longer survival (58 months) and histological aspects suggestive of better prognosis in contrast to the PCT type that had a shorter survival (20 months) and histological characteristics suggestive of worse outcome.

22 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JNJoão M. Fernandes Neto
João M. Fernandes Neto
Ernest NadalErnest Nadal
Ernest Nadal
EBEvert Bosdriesz
Evert Bosdriesz
SOSalo N. Ooft
Salo N. Ooft
LFLourdes Farre
Lourdes Farre
RBRené Bernards
René Bernards
Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibitor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibitor therapy.

1 November 2007 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
ABAchiléa L. Bittencourt
Achiléa L. Bittencourt
MVMaria da Graças Vieira
Maria da Graças Vieira
Carlos BritesCarlos Brites
Carlos Brites
LFLourdes Farre
Lourdes Farre
HBHelenemarie S. Barbosa
Helenemarie S. Barbosa
The purpose of this study was to evaluate whether subdivision of adult T-cell leukemia/lymphoma (ATL) on the basis of clinical types, skin involvemen

14 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
OROctavio A. Romero
Octavio A. Romero
AVAndrea Vilarrubi
Andrea Vilarrubi
JAJuan J. Alburquerque-Bejar
Juan J. Alburquerque-Bejar
AGAntonio Gómez
Antonio Gómez
AAAlvaro Andrades
Alvaro Andrades
MSMontse Sanchez-Cespedes
Montse Sanchez-Cespedes
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. SMARCA4-mutant cells also show an impaired transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX and KDM6B/JMJD3, and a strong dependency on these histone demethylases, so that its inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT), had strong anti-tumour effects. In this work we highlight the vulnerability of KDM6 inhibitors as a characteristic that could be exploited for treating SMARCA4-mutant cancer patients.